Loading...
01/10 16:58
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals declining financial performance, with year-over-year decreases in revenue, EPS, and EBITDA, compounded by geopolitical and economic uncertainties. Despite some positive updates, such as the Milacron sale proceeds and potential market strength in specific regions, the overall guidance reflects a downward trend. The Q&A section highlights management's evasive responses and ongoing market challenges, which could further dampen investor confidence. Given the company's market cap and the current negative sentiment, a negative stock price movement is anticipated over the next two weeks.
Consolidated Revenue $707 million, down 9% year over year due to lower volume and lower starting backlog.
Adjusted Earnings Per Share (EPS) $0.56, down 19% year over year, in line with expectations due to lower starting backlog.
Adjusted EBITDA $97 million, down 15% year over year, as favorable pricing and synergies were offset by lower volume and cost inflation.
Adjusted EBITDA Margin 13.7%, a decrease of 110 basis points year over year, largely due to lower volume.
GAAP Net Income $6 million or $0.09 per share, down from $17 million or $0.24 per share in the prior year, largely due to increased business development and integration costs.
Cash Flow from Operations Use of $11 million, favorable by $13 million compared to the prior year, primarily due to improved working capital efficiency.
Capital Expenditures $10 million in the quarter.
Net Debt $1.7 billion, with a net debt to adjusted EBITDA ratio of 3.4 times.
Backlog $1.6 billion, down 17% year over year.
MTS Revenue $196 million, down 5% year over year due to lower volume, cost inflation, and ongoing pricing pressure.
MTS Adjusted EBITDA $27 million, down 15% year over year.
MTS Adjusted EBITDA Margin 14%, a decrease of 170 basis points year over year.
MTS Backlog $233 million, increased 1% year over year.
Sale of Milacron Business: Hillenbrand announced the sale of approximately 51% of its Milacron injection molding and extrusion business to Bain Capital for $287 million, retaining 49% ownership.
Market Positioning in Food, Health, and Nutrition: The company reported strong order performance in the food, health, and nutrition portfolio, which now represents nearly 30% of total revenue.
Geographic Expansion: Hillenbrand is focusing on growth opportunities in India and the Middle East, capitalizing on a strong geographic footprint.
Operational Efficiencies: Hillenbrand is implementing facility consolidations to create centers of excellence, enhancing capacity utilization.
Cost Synergies: The company is on track to achieve a $30 million run rate cost synergy target by the end of the fiscal year.
Strategic Shift: The sale of Milacron reflects Hillenbrand's transformation towards a higher margin, higher growth portfolio, focusing on industrial leaders in engineered processing equipment.
Economic Factors: The company is facing ongoing uncertainty around inflation, interest rates, and government policy, which are impacting customer order decisions and overall market conditions.
Competitive Pressures: There is significant tariff uncertainty, particularly in the automotive sector, which has slowed new investments and affected demand.
Supply Chain Challenges: The company is monitoring dynamic trade policy discussions and has taken actions to mitigate the impact of tariffs, especially related to China.
Regulatory Issues: Potential impacts of tariff policy in Canada and Mexico are being monitored, but no material impact has been included in the outlook due to the fluid nature of the environment.
Market Demand: Overall order volumes were soft, particularly in capital equipment demand related to plastics projects, indicating a cautious market environment.
Geopolitical Uncertainty: Geopolitical factors are affecting customer order timing, adding to the unpredictability of market conditions.
Milacron Sale: Hillenbrand announced the sale of approximately 51% of its Milacron injection molding and extrusion business to Bain Capital for $287 million, retaining 49% ownership. This transaction is part of Hillenbrand's transformation towards a higher margin, higher growth portfolio.
Portfolio Transformation: The company has divested its secularly declining death care segment and completed several strategic acquisitions to increase scale in food, health, and nutrition markets, now representing nearly 30% of total revenue.
Cost Synergy Target: Hillenbrand is on track to achieve a $30 million run rate cost synergy target by the end of the fiscal year, significantly ahead of the initial timeline.
Debt Reduction Priority: All net proceeds from the Milacron sale will be used for debt pay down, with a focus on reducing leverage.
Fiscal Year 2025 Revenue Guidance: Hillenbrand's full-year revenue guidance is approximately $2.63 billion to $2.8 billion, adjusted for the Milacron transaction.
Adjusted EBITDA Guidance: The adjusted EBITDA guidance for the fiscal year is $411 million.
Adjusted EPS Guidance: The adjusted earnings per share guidance is between $2.45 to $2.80.
Q2 Revenue Guidance: For Q2, Hillenbrand expects revenue of $685 million to $705 million and adjusted earnings per share in the range of $0.53 to $0.58.
CapEx Guidance: Expected capital expenditures for the fiscal year are approximately $45 million.
Quarterly Dividend Returned to Shareholders: Approximately $60 million was returned to shareholders through our quarterly dividend.
Milacron Sale Proceeds: Net proceeds from the Milacron sale will be approximately $250 million, which will be used for debt pay down.
Shareholder Value Maximization: The transaction is expected to maximize shareholder value by concentrating resources on core business and enhancing margin profile.
The earnings call reveals several negative indicators: decreased revenue guidance, lower adjusted EBITDA, and a significant tariff impact. The Q&A highlights uncertainties in cash flow and leverage, with management avoiding clear guidance on dividends. Despite some positive developments in orders and demand, the overall sentiment is cautious due to declining margins and backlog, as well as a competitive pricing environment. Given the market cap, the stock is likely to experience a negative reaction in the range of -2% to -8%.
The earnings call revealed several concerning factors: a decline in revenue and EBITDA, a net loss, and a high net debt ratio. Despite some positive elements like the sale of TerraSource and achieving synergy targets, market volatility and tariff impacts are significant challenges. The Q&A highlighted order delays and management's lack of clarity on inflation impacts. The company's market cap suggests moderate sensitivity to these issues, leading to a predicted negative stock price movement of -2% to -8%.
The earnings call reveals several challenges: a revenue decline, cost inflation, backlog reduction, and deleveraging issues. Despite some positive developments like the TerraSource sale for debt reduction, the financial performance is weak, with a significant year-over-year decrease in revenue and adjusted EBITDA. The Q&A section highlights management's lack of clarity on tariffs and future orders, further contributing to uncertainty. Given these factors and the company's small-cap status, a negative stock price movement of -2% to -8% is expected.
The earnings call reveals declining financial performance, with year-over-year decreases in revenue, EPS, and EBITDA, compounded by geopolitical and economic uncertainties. Despite some positive updates, such as the Milacron sale proceeds and potential market strength in specific regions, the overall guidance reflects a downward trend. The Q&A section highlights management's evasive responses and ongoing market challenges, which could further dampen investor confidence. Given the company's market cap and the current negative sentiment, a negative stock price movement is anticipated over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
